Saturday 17 October 2026
Export TRVI’s income statement to Excel — free account
Trevi Therapeutics, Inc.
TRVI Healthcare Biotechnology
In the quarter to June 2026, EPS fell 22.2% and free cash flow fell 73.8%, each against the same quarter a year earlier.
11.87
0.24
−1.98%
Follow TRVI
Trevi Therapeutics, Inc. (TRVI) P/E ratio
Trevi Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ZBIO Zenas BioPharma, Inc. compare | n/m |
| TRVI Trevi Therapeutics, Inc. | n/m |
| MESO Mesoblast Limited compare | n/m |
| BHVN Biohaven Ltd. compare | n/m |
| SEPN Septerna, Inc. compare | n/m |
| URGN Urogen Pharma compare | n/m |
| VIR Vir Biotechnology, Inc. compare | n/m |
| XNCR Xencor, Inc. compare | n/m |
| NUVB Nuvation Bio Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)